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SUMMARY
Alzheimer’s disease is characterized by intracerebral
deposition of b-amyloid (Ab). While Ab40 is the most
abundant form, neurotoxicity is mainly mediated
by Ab42. Sequential cleavage of amyloid precursor
protein (APP) by b- and g-secretases gives rise to
full-length Ab (Ab1-x) and N-terminally truncated Ab
0
(Ab11-x) whereas cleavage by a- and g-secretases
leads to the shorter p3 peptides (Ab17-x). We uncov-
ered significantly higher ratios of 42- versus 40-
ending variants for Ab and Ab0 than for p3 secreted
by mouse neurons and human induced pluripotent
stem cell (iPSC)-derived neurons or produced in a
cell-free g-secretase assay with recombinant APP-
CTFs. The 42:40 ratio was highest for Ab0, followed
by Ab and then p3. Mass spectrometry analysis
of APP intracellular domains revealed differential
processing of APP-C83, APP-C89, and APP-C99 by
g-secretase already at the ε-cleavage stage. This
mechanistic insight could aid in developing sub-
strate-targeted modulators of APP-C99 processing
to specifically lower the Ab42:Ab40 ratio without
compromising g-secretase function.
INTRODUCTION
Alzheimer’s disease (AD), the most common neurodegenerative
disease, is causally linked to the accumulation of misfolded
b-amyloid (Ab) peptides within the brain (Huang and Mucke,
2012; Selkoe, 2011). Ab peptides, the length of which can vary
from 37 to 43 amino acids (aa), are generated in the so-called
amyloidogenic pathway through sequential proteolytic cleavage
of the type-1 transmembrane amyloid precursor protein (APP) by
two secretase entities, the aspartyl protease b-site APP cleaving
enzyme 1 (BACE1, also termed b-secretase) and the tetrameric
g-secretase complex. b-secretase can cleave APP at two alter-
native sites, either at Asp1 or at Glu11 of the Ab sequence, leading
to the generation of a 99 aa C-terminal fragment (CTF) (C99) or a
89 aa CTF (C89) that will then be further processed by g-secre-
tase to full-length Ab1-x (Ab) or the N-terminally truncated Ab11-x
(Ab0), respectively (Thinakaran and Koo, 2008; Zhang et al.,
2012). While Ab0 appears to be the predominant species
secreted by neurons and to contribute to the formation of insol-
uble aggregates in the brains of AD patients (Cai et al., 2001;
Gouras et al., 1998; Liu et al., 2006), the two most abundant
Ab species found in senile plaques are Ab42 and Ab40. Production
of Ab and Ab0 is precluded if APP is processed by a-secretase
that cleaves within the Ab sequence. The resulting 83 aa CTF
(C83) is subsequently processed by g-secretase, releasing the
p3 peptide (Ab17-x). These 3 kDa peptides are non-amyloido-
genic but contribute to the formation of non-congophilic, diffuse
plaques in the cerebellum of Down syndrome patients and
different brain regions of AD patients (Gowing et al., 1994; Hig-
gins et al., 1996; Lalowski et al., 1996). The pathological signifi-
cance of this p3 accumulation is not yet understood.
The different C-terminal variants of Ab, Ab0, and p3 that are
produced by g-secretase arise from the carboxypeptidase-like
trimming (g-cleavage) of slightly longer membrane bound
peptides that are generated through the initial endoproteolytic
cleavage (ε-cleavage) of the respective APP CTFs. Whether the
g-secretase-mediated cleavage of APP-bCTFs and APP-aCTF
is comparable with respect to the relative production of the
different C-terminal variants of Ab, Ab0, and p3 is not known
yet. The interpretation of data obtained from brain homogenates
or cerebrospinal fluid (CSF) samples is difficult, since steady-
state levels of the different Ab, Ab0, and p3 species in the brain
are determined not only by their production but also by the
continuous clearance through microglial phagocytosis and
transport across the blood-brain barrier.
Here, we studied the relative levels of production of C-terminal
variants of Ab, Ab0, and p3 in cellular systems where analyte
levels are not significantly affected by microglial activity or
sequestration into the blood stream (mouse primary neuronal
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Figure 1. Interference with b-Secretase and with a-Secretase-Mediated APP-Processing Decreases and Increases, Respectively, the 42:40
Ratio of [Ab/Ab0+p3] Secreted by Mouse Primary Neurons
Wild-type mouse primary neurons were treated with b-secretase inhibitor (C3; 1 mM), a-secretase inhibitor (TAPI-1; 40 mM) or g-secretase inhibitor (DAPT; 1 mM)
or transfected with siRNAs targeting APP, BACE1, ADAM10, or PSEN1.
(A) Inhibitor-treated neurons. Top: relative [Ab/Ab0+p3]40 and [Ab/Ab0+p3]42 levels. Bottom: [Ab/Ab0+p3]42:40 ratio (n = 6 for C3 and TAPI-1; n = 4 for DAPT).
Average ± SD. **p < 0.01; ***p < 0.001.
(B) siRNA-transfected neurons. Top: relative [Ab/Ab0+p3]40 and [Ab/Ab0+p3]42 levels. Table: mRNA knockdown efficiencies as analyzed by real-time PCR.
Bottom: [Ab/Ab0+p3]42:40 ratio (n = 8 for BACE1 and PSEN1-siRNA; n = 5 for APP and ADAM10). Average ± SD. ***p < 0.001.
(legend continued on next page)
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cultures and human induced pluripotent stem cell [iPSC]-derived
neurons), as well as in a cell-free assay with purified g-secretase.
We made the surprising discovery that the 42:40 ratio is signifi-
cantly different for all three peptide species (Ab0 > Ab > p3) as
a consequence of differential g-secretase-mediated ε-cleavage
of the respective APP-CTFs. Our results could serve as a starting
point for therapeutic deliberations that aim at altering specifically
the Ab production profile without changing physiological levels
of other APP cleavage products nor interfering with the process-
ing of other b-secretase and g-secretase substrates.
RESULTS
For analysis of 40- and 42-ending C-terminal variants of p3 and
Ab/Ab0 within the same assay, we used an electrochemilumines-
cence (ECL) multiplex immunoassay with C terminus-specific
capture antibodies and a detection antibody that recognizes
Ab, Ab0, and p3 peptides alike (4G8 monoclonal antibody
[mAb]). In this way, we detected the total of all three peptides,
discriminating only between the C termini. To uncover possible
differences in the relative production of 40- and 42-ending vari-
ants of Ab/Ab0 versus p3 secreted bymouse primary neurons, we
interfered with either the production of APP-bCTFs or APP-aCTF
(in order to have only p3 or only Ab/Ab0 produced, respectively)
andmonitored the 42:40 ratios in comparison to the control con-
dition where all analytes were present. Suppression of Ab/Ab0
production was achieved through incubation with b-secretase
inhibitor and led to a strong reduction of the 42:40 ratio as the
result of a more pronounced decrease of the [Ab/Ab0+p3]42
signal compared to the [Ab/Ab0+p3]40 signal (Figure 1A). Sup-
pression of p3 production through a-secretase inhibition, on
the other hand, increased the 42:40 ratio. For validation of our
initial finding with a different method, we performed small inter-
fering RNA (siRNA)-mediated knockdowns of either BACE1,
the predominant b-secretase of APP (Cai et al., 2001; Vassar
et al., 1999), or ADAM10, the predominant a-secretase of APP
in neurons (Jorissen et al., 2010; Kuhn et al., 2010; Postina
et al., 2004). Knockdown of BACE1 produced a pronounced
decrease of the [Ab/Ab0+p3] 42:40 ratio whereas knockdown of
ADAM10 increased the 42:40 ratio (Figure 1B), highly similar to
the shift observed upon b-secretase and a-secretase inhibition.
Importantly, simultaneous reduction of Ab/Ab0 and p3 by partial
knockdown of APP or PSEN1, the catalytic subunit of the g-sec-
retase complex, did not alter the 42:40 ratio of the Ab/Ab0+p3
signal (Figure 1B), demonstrating that, under physiological con-
ditions, a concentration shift between substrate (APP-CTF) and
enzyme (g-secretase) is not sufficient to reduce the 42:40 ratio,
contrary to what has been observed in mutant APP transgenic
cells by a previous study (Yin et al., 2007).
So far, our data show that the 42:40 ratio of the Ab/Ab0+p3
signal is reduced when the obtained signal is contributed mainly
by p3 ( = upon suppression of Ab and Ab0 production by interfer-
ence with b-secretase) and increased when mainly Ab and Ab0
are produced ( = upon suppression of p3 production by interfer-
ence with a-secretase).
This suggests that either Ab/Ab0 are produced at a significantly
higher 42:40 ratio than p3, or that interference with b-secretase
or a-secretase indirectly affects g-secretase-mediated process-
ing of APP-CTFs. In order to dissect these two scenarios, we
analyzed the 42:40 ratio of Ab itself, which is expected to remain
stable only in the first scenario. For specific detection of murine
Ab40 and Ab42 we combined the ECL multiplex platform with a
detection antibody (M3.2 mAb) that binds within aa 10–15 of
murine Ab, N-terminally of the APP a-secretase cleavage site.
When analyzing specifically Ab, we no longer observed a shift
in the 42:40 ratio (Figures 1C and 1D). Both Ab42 and Ab40
decreased in a highly comparable manner upon b-secretase in-
hibition or knockdown of BACE1 and increased upon a-secre-
tase inhibition or ADAM10 knockdown. We therefore conclude
that the observed 42:40 shift of the Ab/Ab0+p3 signal upon inter-
ference with b-secretase or a-secretase is indeed due to a higher
42:40 ratio for Ab/Ab0 peptides than for p3 peptides.
To test if our finding has a bearing in a more relevant context
to humans, we validated our results in human iPSC-derived
neurons. In agreement with our data from mouse primary neu-
rons, we detected a disproportional decrease of [Ab/Ab0+p3]42
compared to [Ab/Ab0+p3]40 upon b-secretase inhibitor treat-
ment, whereas a-secretase inhibition increased the 42:40 ratio
(Figure 2A). The efficacy of b-secretase and a-secretase inhibi-
tion was monitored by ECL analysis of sAPPb and sAPPa (Fig-
ure 2B). The ratio of Ab42 to Ab40 was again unchanged in both
setups (Figure 2C).
Taken together, our results thus far show that both mouse and
human neurons produce Ab/Ab0 peptides at a significantly higher
42:40 ratio than p3 peptides. This finding suggests that APP
b-CTFs and a-CTFs are differentially processed by g-secretase.
What could cause this differential processing? Previous studies
have described substrate specificity (cleavage of APP versus
Notch) as well as differences in ε- and g-processing (generation
of different Ab profiles) for specific g-secretase complex compo-
sitions (Acx et al., 2014; Serneels et al., 2009).We considered the
possibility that also APP b-CTFs and a-CTF might be processed
by different g-secretase complexes and that this specificity
results in higher 42:40 ratios for Ab/Ab0 as compared to p3.
A functional g-secretase complex requires the assembly of
four essential subunits: presenilin (PSEN), nicastrin (NCSTN),
anterior pharynx-defective protein 1 (APH1), and presenilin
enhancer g-secretase subunit (PSENEN) (Edbauer et al., 2003).
Both PSEN and APH1 show genetic heterogeneity, which per-
mits the formation of at least four different g-secretase com-
plexes in human and six different complexes in mouse (He´bert
et al., 2004). To test our hypothesis, we systematically interfered
with the formation of the individual g-secretase complexes
by siRNA-mediated knockdown of PSEN homologs (PSEN1,
(C) Inhibitor-treated neurons. Relative Ab40 and Ab42 levels (n = 5 for C3; n = 7 for TAPI-1; n = 4 for DAPT). Average ± SD.
(D) siRNA-transfected neurons. Relative Ab40 and Ab42 levels (n = 5 for APP, BACE1, and PSEN1; n = 4 for ADAM10). Average ± SD.
(E)Western blot analysis of APP-full length and APP b-CTF upon b-, a-, and g-secretase inhibitor treatment and validation of knockdown efficiency at protein level
for APP, BACE1, PSEN1, and ADAM10.
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PSEN2) or APH1 homologs (APH1A, APH1B, APH1C) in mouse
primary neurons and analyzed the 40:42 ratio of Ab/Ab0+p3 un-
der basal conditions as well as upon b-secretase inhibitor treat-
ment. Loss of PSEN or APH1 heterogeneity left the 40:42 ratio
unchanged under basal conditions and did not affect the 42:40
ratio shift that occurs upon b-secretase inhibition (Figure 3A).
These data suggest that the different 42:40 ratios of Ab/Ab0
versus p3 do not require the action of different g-secretase com-
plexes. While we are aware that silencing of the PSEN and APH1
homologs was incomplete, we believe that, with a knockdown
efficiency of >60% at mRNA level and confirmed reduction at
protein level for all detectable subunits (Figure 3B), individual
g-secretase complex subtypes have been sufficiently reduced
to uncover possible effects.
Having shown that g-secretase heterogeneity is not crucial for
the differential processing of APP aCTF and bCTFs, we next
studied whether the differential processing could be attributed
to the substrates themselves. The two APP b-CTFs (C99 and
C89) differ from APP a-CTF (C83) by an extended N terminus
(16 aa and 10 aa, respectively) that might affect the positioning
of the substrate toward the g-secretase complex, thereby
dictating the ε-cleavage site for initial proteolysis and conse-
quently defining whether 40- or 42-C-terminal fragments are
generated during the subsequent g-cleavage steps (Olsson
et al., 2014; Takami et al., 2009). Cleavage might also be modu-
lated by the different pH of the subcellular compartments where
g-secretasemeets APP a-CTF or b-CTFs.While a-secretase can
cleave APP already at the cell surface, efficient b-secretase
cleavage of APP requires the low pH of the endocytic compart-
ment (Haass et al., 2012; Perez et al., 1999; Rajendran et al.,
2006, 2008; Vassar et al., 1999). With active g-secretase being
present at both plasma membrane and endosomes (Kaether
et al., 2006; Tarassishin et al., 2004), g-secretase cleavage is
Figure 2. b-Secretase and a-Secretase In-
hibition Decreases and Increases, Respec-
tively, the 42:40 Ratio of [Ab/Ab0+p3]
Secreted by Human iPSC-Derived Neurons
Human iPSC-derived neurons were treated with
b-secretase inhibitor (C3; 1 mM) or a-secretase
inhibitor (TAPI-1; 40 mM). Data are displayed as
average ± SD of the averaged quadruplicate
measurements for the two lines of human iPSC-
derived neurons.
(A) Relative levels of [Ab/Ab0+p3]40 and [Ab/
Ab0+p3]42 as analyzed by ECL assay (left) and
the respective [Ab/Ab0+p3] 42:40 ratios (right).
*p < 0.05; **p < 0.01; ***p < 0.001.
(B) Relative levels of sAPPb and sAPPa as
analyzed by ECL assay. **p < 0.01; ***p < 0.001.
(C) Relative levels of Ab40 and Ab42 as analyzed by
ECL assay.
likely to occur immediately after a- and
b-cleavage in the respective subcellular
compartments. To directly study the in-
fluence of substrate identity (APP-CTFs
C83, C89, and C99) and pH environment
on the 42:40 ratio of p3, Ab0, and Ab, we
took advantage of a cell-free assay (Dimitrov et al., 2013) where
recombinant human APP C83-His, C89-His, or C99-His sub-
strates were incubated together with purified g-secretase at
four different pH (pH 5.5, pH 6.5, pH 7.5, and pH 8.5). Analysis
of total APP intracellular domain (AICD) levels by western blot
and analysis of Ab, Ab0, and p3 by ECL-assay showed highest
g-secretase activity at pH 6.5, in line with previous findings
(Fraering et al., 2004; McLendon et al., 2000) (Figure 4A). Inter-
estingly, the 42:40 ratio consistently decreased with lower pH
for all three analytes (Ab, Ab0, and p3) (Figure 4A), suggesting
that the low pH environment of the cellular endocytic compart-
ment where Ab and Ab0 are produced does not contribute to
the higher 42:40 ratio as compared to p3. The substrate itself
(APP-CTF), however, had a strong influence on the 42:40 ratio
of the respective cleavage products produced by g-secretase.
In a first experiment, where only APP C99 and C83 were studied,
the 42:40 ratio of Abwas found to be 2-fold higher than the 42:40
ratio of p3 peptides, and it was 1.4-fold higher in a second and
third experiment, where all three APPCTFswere analyzed in par-
allel (Figure 4B). Very surprisingly, the 42:40 ratio of Ab0 did not
resemble either Ab or p3, nor did it fall between these two, but
it even exceeded the 42:40 ratio of Ab (by 1.6-fold and 3.2-fold
in experiment 2 and 3, respectively) (Figure 4B). To understand
whether the different 42:40 ratios of Ab, Ab0, and p3 result from
differential ε-cleavage or g-cleavage of the respective APP-
CTFs, we analyzed the AICD profiles generated from C83,
C89, and C99 by mass spectrometry. Two different production
lines have been postulated for the generation of Ab40 and Ab42
(Figure 4C), each of which is associated with the generation of
one distinct AICD. The AICD49–99 is produced in the Ab42 line
and AICD50–99 in the Ab40 line (Olsson et al., 2014; Takami
et al., 2009). Mass spectrometry analysis showed that all three
APP-CTFs gave rise to these two AICD species (Figure 4D).
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However, the relative peak intensity of both AICDs differed
significantly between the different substrates. The highest ratio
of AICD49–99:AICD50–99 was produced from APP C89, followed
by C99 and then by C83 (Figure 4D). The AICD49–99:AICD50–99 ra-
tios produced from C89, C99, and C83 thus follow the same or-
der as the 42:40 ratios for Ab0, Ab, and p3. This suggests that the
different 42:40 ratios are the consequence of differential ε-cleav-
age of the three APP-CTFs by g-secretase.
It is intriguing that the 42:40 ratio of Ab0 does not fall in between
Ab and p3 and that it is even higher than for Ab. We wanted to
validate this observation in a cellular setting using a previously
characterized pertinent mutation in APP. The Leuven mutation
(APP695E607K) affects the alternative b-secretase cleavage site
at position +11 and shifts b-secretase cleavage to the +1 site
(Zhou et al., 2011). This shift results in more full-length Ab at
the expense of Ab0 and would allow us to detect differences in
the 42:40 ratios between both peptides. As a cellular system,
we used HEK293 cells that stably express BACE1 (HEK-
BACE1), which show dominant b-secretase activity (Figure 5A)
and negligible contribution of endogenous APP-derived prod-
ucts to the obtained Ab/Ab0+p3 signal (the low reads from
GFP-transfected cells were insensitive to g-secretase inhibition
and therefore considered as unspecific background; data
not shown). HEK-BACE1 cells were transfected with plasmids
expressing either wild-type human APP695, the Leuven mutation
APP695E607K or one of two other +11 site mutations (APP
695
E607A
and APP695D607). Western blot analysis of APP b-CTFs under
g-secretase inhibitor treatment showed an increased APP
C99:C89 ratio (a shift from the +11 to the +1 site) for APP695E607K
and for APP695D607 (Figure 5B). At the same time, the 42:40 ratio
of the Ab/Ab0+p3 signal was significantly decreased for these
two mutations as compared to APP695wild-type (Figure 5C). This
difference was abolished by b-secretase inhibitor treatment
and unaffected by a-secretase inhibitor treatment, demon-
strating that it is produced solely by b-secretase cleavage-
derived products (Ab+Ab0). Because both the APP695E607K and
the APP695D607 mutation increase the C99:C83 ratio and accord-
ingly the Ab:Ab0 ratio, the lower 42:40 ratio of the obtained
Ab+Ab0 signal can thus be attributed to a lower 42:40 ratio of
full-length Ab as compared to Ab0, which confirms our results
from the cell free g-secretase assay.
In summary, our results describe a differential processing of
the three main APP-CTFs (C99, C89, and C83) by g-secretase.
Differential processing is initiated at the level of ε-cleavage, lead-
ing to different AICD49–99:AICD50–99 ratios produced from C99,
C89, and C83, and continues during g-cleavage that results in
significantly different 42:40 ratios for Ab, Ab0, and p3 peptides.
DISCUSSION
The three major APP-CTFs (C99, C89, and C83) differ only in the
length of their ectodomains and in their free N termini. g-Secre-
tase cleavage takes place within the hydrophobic environment
of the membrane lipid bilayer that is not accessible to the hydro-
philic N terminus. This raises the question as to how the different
ectodomains modulate ε-/g-cleavage of the respective APP-
CTFs. Substrate recruitment by g-secretase was initially pro-
posed to require interaction of the substrate’s free N terminus
Figure 3. Limiting g-Secretase Complex Heterogeneity by Knock-
down of PSEN or APH1 Subunit Homologs Does Not Change the [Ab/
Ab0+p3] 42:40 Ratio
Mouse primary neurons were transfected with siRNAs targeting APH1A,
APH1B, APH1C, PSEN1, or PSEN2 (n = 3) and treated with DMSO or b-sec-
retase inhibitor (C3; 1 mM).
(A) Relative [Ab/Ab0+p3] 42:40 ratios as analyzed by ECL. Average ±SD. Table:
mRNA knockdown efficiencies as analyzed by real-time PCR.
(B) Western blot analysis of protein levels for the different knockdown condi-
tions. APH1B/C signal was not detectable (see Figure S2).
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with the nicastrin ectodomain (Shah et al., 2005). However, this
model was challenged by independent functional studies that
could not establish a role for the substrate’s N terminus, or the
substrate’s ectodomain generally, in the recruitment by g-secre-
tase (Bolduc et al., 2016; Cha´vez-Gutie´rrez et al., 2008). Instead,
nicastrin’s bulky ectodomain was found to play a role in passive
substrate sorting by sterically blocking the access of substrates
that have not yet undergone shedding by a- or b-secretase (Bol-
duc et al., 2016). Interestingly, even for shed substrates, cleav-
age efficiency appears to decline with increasing ectodomain
length, making APP C99 a less favored g-secretase substrate
than APP C83 (Funamoto et al., 2013). We observed, however,
no correlation of that type between the APP-CTF ectodomain
length and the 49–99:50–99 ratios of AICDs or the 42:40 ratios
of Ab, Ab0, and p3 peptides. APP-C89, which has an ectodomain
length that ranges between APP-C83 and APP-C99, produced
the highest 49–99:50–99 and 42:40 ratios of all three APP-
CTFs. The APP-CTF ectodomain length per se is thus not able
to modulate g-secretase-mediated ε- or g-cleavage into a spe-
cific direction.
The APP-CTF ectodomain features a so-called APP substrate
inhibitory domain (ASID) that comprises a stretch of five hydro-
phobic residues (LVFFA; corresponding to Ab 17–21), which
interact with PSEN and negatively regulate g-secretase activity
in an allosteric manner (Fukumori and Steiner, 2016; Tian et al.,
2010). Interestingly, deletion and mutations of this region dispro-
portionally affect Ab40 and Ab42 production in both cell-based
and in vitro assays (De Jonghe et al., 1998; Tang et al., 2014;
Tian et al., 2010). Structural analysis of APP-C99 revealed that
the LVFFA motif forms the central stretch of a surface-associ-
ated a-helix that is flanked by a short juxtamembrane luminal
loop that connects to the transmembrane domain (TMD) and
by a disordered 16 aa stretch on the N-terminal side (Beel
et al., 2008; Nadezhdin et al., 2011; Pester et al., 2013). It is
conceivable that the proposed membrane-embedding of the
ASID helix (Beel et al., 2008) and its mobility within the bilayer
differ slightly between the three APP-CTFs as a result of the
different numbers of residues located N-terminal of the helix
and their intermolecular interactions with e.g., the nicastrin ecto-
domain or lipid headgroups of the membrane. This could affect
the interaction of ASID with PSEN and/or modulate the accessi-
bility and helical stability of the ε-cleavage sites Thr48 and Leu49
in APP-TMD through direct or allosteric effects as seen for famil-
ial AD mutations (Chen et al., 2014) and translate into differential
ε-/g-cleavage. In APP-C83, the 16 aa N-terminal truncation as
compared to APP-C99 moves the N terminus to the first residue
of the LVFFA domain thereby rendering the otherwise hydropho-
bic leucine positively charged and directly affecting the ASID
motif. In APP-C89, the 10 aa N-terminal truncation removes
most of the residues that have been identified by photoaffinity
mapping to be the primary contact sites with nicastrin (Fukumori
and Steiner, 2016). The mobility of the ASID harboring ectodo-
main of APP-C89 is therefore expected to be much less affected
by nicastrin than the ectodomain of APP-C99.
Our pH profiling analysis suggests that, in addition to
substrate identity, the pH of the subcellular compartment
where g-secretase cleavage takes place can additionally modu-
late the interaction between APP-CTFs and g-secretase. This
Figure 4. Differential ε-Cleavage of APP C83, C99, and C89 Results in Different 42:40 Ratios for p3, Ab, and Ab0
Recombinant APP C83-His, APP C99-His, or APP C89-His were cleaved by purified g-secretase at different pH.
(A) Top: Western blot analysis of AICD-His. Bottom: ECL-analysis of relative p3, Ab, and Ab0 levels. Average ± SD of triplicate measurements.
(B) ECL analysis of 42:40 ratios of p3, Ab, and Ab0 (pH 6.5). Average ± SD of triplicate measurements.
(C) Postulated model for g-secretase-mediated processing of APP C99 where Ab42 and Ab40 are generated in two different production lines.
(D) Immunoprecipitation (IP) MALDI-TOF mass spectrometry analysis of AICD species generated from C83-His, C99-His, and C89-His. Table: AICD49–99:
AICD50–99 ratios as estimated from peak intensities.
Figure 5. A Shift from Ab0 to Ab Production Is Associated with Lower 42:40 Ratios
HEK-BACE1 cells were transfected with different APP-expressing constructs and treated with DMSO, b-secretase inhibitor (C3; 2 mM), or a-secretase inhibitor
(TAPI-1; 40 mM).
(A) ECL analysis of relative sAPPa and sAPPb levels (n = 3). Average ± SD.
(B) Western blot analysis of APP full-length and APP-CTFs in DAPT-treated cells.
(C) ECL-analysis of 42:40 ratios of [Ab/Ab0+p3]. n = 3; average ± SD. **p < 0.01.
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modulation would, however, not contribute to the higher 42:40
ratios observed for Ab and Ab0 because the 42:40 production ra-
tios were found to decrease in low pH conditions, representative
of the endocytic compartment where APP-bCTFs are produced.
Our data point to the substrate itself as the major determinant for
the differential processing of the three APP-CTFs. Considering
the high neurotoxicity that is caused by Ab42 as compared to
Ab40, onewonders whether the newly acquired knowledge about
the impact of the different APP-CTF ectodomains on g-secre-
tase cleavage can be exploited to modulate the processing of
APP-C99 so as to specifically lower the production of toxic
Ab42. By physically shielding the N-terminal region of APP-C99
it should be possible to confine the interaction with g-secretase
to APP-C83 residues. Such masking might render g-secretase
processing of APP-C99 more ‘‘C83-like’’ and reduce the result-
ing Ab 42:40 ratio. Our finding that the 42:40 ratio of Ab0 that is
produced from APP C89 exceeds the 42:40 ratio of Ab suggests
that a successful modulation into the desired direction would
require masking of the entire 16 N-terminal amino acids of APP
C99 in order to avoid ‘‘C89-like’’ processing. However, because
the actual outcome of such manipulations is hardly foreseeable,
especially with respect to the previously discussed intermolec-
ular interactions of the APP-CTF ectodomain with nicastrin
and/or the membrane surface and its impact on the ASID helix,
a systematic experimental testing is needed to identify the
optimal approach. Modulation of APP-bCTF processing by tar-
geting the substrate itself would have a significant advantage
over classical strategies that aim at reducing Ab production
through inhibition of b-secretase or g-secretase, that is the
unperturbed processing of all physiological b-secretase and
g-secretase substrates. Importantly, this includes APP, which
is the precursor not only for Ab but also for several other
cleavage products (e.g., p3, sAPPa, sAPPb, and AICD) that
can affect physiological functions on their part (Chasseigneaux
and Allinquant, 2012; Nhan et al., 2015). An intervention strategy
that would allow us to modulate specifically the Ab production
profile without compromising the processing of other b-secre-
tase and g-secretase substrates nor altering physiological
levels of other APP cleavage products would therefore be highly
desirable in order to minimize the risk of potential negative side
effects.
EXPERIMENTAL PROCEDURES
Mouse Primary Neuronal Cultures
Mixed cortical/hippocampal primary neuronal cultures were prepared from
E16 ICR (CD-1) outbred mice (Harlan Laboratories). All animal experiments
were done according to the guidelines of and approved by the veterinary office
of the Canton of Z€urich, Switzerland. For details see the Supplemental Exper-
imental Procedures.
Human iPSC-Derived Neurons
iPSCs from two healthy male donors (33 and 34 years old) have been gener-
ated previously (Mertens et al., 2013). For details on neuronal differentiation
and culture conditions see the Supplemental Experimental Procedures.
siRNA Transfection
4DIV primary neurons were transfected with 100 nM of siRNA (stealth siRNA,
Life Technologies) using Lipofectamine RNAiMax (Life Technologies) as trans-
fection reagent. For details see the Supplemental Experimental Procedures.
Inhibitor Treatment
The following inhibitors were used: a-secretase inhibitor TAPI-1, b-secretase
inhibitor IV, and g-secretase inhibitor DAPT (all from Calbiochem, Merck Milli-
pore). 7 days in vitro (DIV) primary neurons and HEK-BACE1 cells were treated
for 24 hr (72 hr post-transfection), human iPSC-derived neurons for 20 hr
(following a preincubation for 16 hr).
Electrochemiluminescence Assay
Twenty-four hour conditioned medium of 8DIV mouse primary neurons or HEK-
BACE1 cells (72 hr post-transfection) or 20 hr conditioned medium of human
iPSC-derived neurons was used for analysis. Mouse or human [Ab/Ab0+p3]40
and [Ab/Ab0+p3]42 were analyzed with the Ab-Panel-1 Kit (4G8) (Meso-Scale-
Discovery). Murine Ab40 and Ab42 were analyzed with the Ab-Panel-1 Kit assay
plate (Meso-Scale-Discovery) together with SULFO-TAG anti mouse/rat-Ab
(M3.2 mAb) antibody. sAPPa and sAPPb were analyzed with the sAPPa/sAPPb
multiplex assay (Meso-Scale-Discovery). Standard curves are depicted in
Figure S1. For details see the Supplemental Experimental Procedures.
g-Secretase Activity Assay
g-Secretase assays using recombinant human APP C99-His, C89-His,
and C83-His were performed as previously reported (Cacquevel et al., 2008;
Dimitrov et al., 2013; Wu et al., 2010). For details see the Supplemental Exper-
imental Procedures.
Statistical Analysis
Data are represented as average ± SD. All p values were determined using
two-tailed Student’s t test. Paired testing was applied for comparison of
different relative analyte levels within a given experimental condition. Unpaired
testing was performed for comparison to the control condition.
Additional information on materials and methods can be found in Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2017.05.034.
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